| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
ROCKVILLE, Md.—In a deal that could reach $5 million, Novavax announced it signed a non-exclusive worldwide license agreement with Wyeth for rights to the latter's virus-like particle (VLP) technology for vaccine development. The deal includes upfront payments, as well as annual license fees, milestone payments, and royalties on sales of products arising from the deal.
 
"We are delighted to have completed this license agreement with Wyeth and see this license as another important step in building a strong intellectual property position for our influenza vaccine programs," says Rahul Singhvi, Novavax president and CEO.
 
VLPs have gained much attention in recent years as various labs worldwide have suggested that the protein complexes are able to induce stronger immune responses than typical vaccine antigens because of their structural similarity to viruses. Unlike viruses, however, VLPs lack genetic material and are therefore non-infectious.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue